Get the Stockscreener App
138.37
1.40%
-1.96
After Hours:
138.13
-0.24
-0.17%
Biogen Inc stock is traded at $138.37, with a volume of 1.09M.
It is down -1.40% in the last 24 hours and down -1.08% over the past month.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
See More
Previous Close:
$140.33
Open:
$140.6
24h Volume:
1.09M
Relative Volume:
0.74
Market Cap:
$20.25B
Revenue:
$9.61B
Net Income/Loss:
$1.62B
P/E Ratio:
12.50
EPS:
11.07
Net Cash Flow:
$1.77B
1W Performance:
-1.80%
1M Performance:
-1.08%
6M Performance:
-28.92%
1Y Performance:
-35.83%
1-Day Range:
$138.20
$141.25
1-Week Range:
$138.20
$144.15
52-Week Range:
$128.51
$238.00
Biogen Inc Stock (BIIB) Company Profile
Name
Biogen Inc
Sector
Industry
Phone
(781) 464-2000
Address
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
138.37 | 20.25B | 9.61B | 1.62B | 1.77B | 11.07 |
|
LLY
Lilly Eli Co
|
822.51 | 738.75B | 45.04B | 10.59B | 414.30M | 11.71 |
|
ABBV
Abbvie Inc
|
205.29 | 363.15B | 56.33B | 4.28B | 17.83B | 2.40 |
|
JNJ
Johnson Johnson
|
163.71 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
NVO
Novo Nordisk Adr
|
69.30 | 311.44B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
MRK
Merck Co Inc
|
89.23 | 225.40B | 64.17B | 17.12B | 18.10B | 6.73 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-25 | Initiated | Bernstein | Mkt Perform |
| Jan-02-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
| Nov-18-24 | Downgrade | Needham | Buy → Hold |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-31-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Feb-14-24 | Reiterated | Needham | Buy |
| Feb-14-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Dec-20-23 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-07-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-24-23 | Reiterated | UBS | Buy |
| May-01-23 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-17-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-26-22 | Upgrade | Goldman | Neutral → Buy |
| Oct-13-22 | Upgrade | Stifel | Hold → Buy |
| Oct-07-22 | Upgrade | Argus | Hold → Buy |
| Sep-28-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Sep-28-22 | Upgrade | Mizuho | Neutral → Buy |
| Sep-28-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-18-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-22 | Downgrade | Stifel | Buy → Hold |
| Mar-03-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-04-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-04-22 | Reiterated | Barclays | Equal Weight |
| Feb-04-22 | Reiterated | BofA Securities | Neutral |
| Feb-04-22 | Reiterated | Cowen | Outperform |
| Feb-04-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-04-22 | Reiterated | Needham | Buy |
| Feb-04-22 | Reiterated | Oppenheimer | Outperform |
| Feb-04-22 | Reiterated | RBC Capital Mkts | Sector Perform |
| Feb-04-22 | Reiterated | Robert W. Baird | Neutral |
| Feb-04-22 | Reiterated | Wedbush | Neutral |
| Feb-04-22 | Reiterated | Wells Fargo | Equal Weight |
| Feb-04-22 | Reiterated | Wolfe Research | Peer Perform |
| Jan-13-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-12-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Jun-18-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-14-21 | Reiterated | Truist | Buy |
| Jun-11-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jun-10-21 | Upgrade | UBS | Neutral → Buy |
| Jun-08-21 | Upgrade | Atlantic Equities | Underweight → Neutral |
| Jun-08-21 | Reiterated | Barclays | Equal Weight |
| Jun-08-21 | Upgrade | Citigroup | Sell → Neutral |
| Jun-08-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-08-21 | Reiterated | Jefferies | Buy |
| Jun-08-21 | Reiterated | Morgan Stanley | Overweight |
| Jun-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-08-21 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Jun-08-21 | Reiterated | Stifel | Buy |
| Jun-08-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-07-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-07-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-07-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-05-21 | Downgrade | DZ Bank | Buy → Hold |
| Jan-29-21 | Upgrade | Stifel | Hold → Buy |
| Nov-10-20 | Upgrade | DZ Bank | Hold → Buy |
| Nov-09-20 | Downgrade | Atlantic Equities | Neutral → Underweight |
| Nov-09-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-09-20 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-04-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Nov-04-20 | Upgrade | Jefferies | Hold → Buy |
| Nov-04-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Jul-27-20 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jun-22-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-22-20 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Apr-23-20 | Downgrade | Citigroup | Neutral → Sell |
| Apr-23-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-27-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-13-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Dec-02-19 | Downgrade | Robert W. Baird | Neutral → Underperform |
View All
Biogen Inc Stock (BIIB) Latest News
Rep. Robert Bresnahan, Jr. Buys Biogen Inc. (NASDAQ:BIIB) Shares - MarketBeat
Beutel Goodman & Co Ltd. Buys 2,323 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Shares Acquired by NEOS Investment Management LLC - MarketBeat
Thrivent Financial for Lutherans Sells 172,817 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Virtu Financial LLC Decreases Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Prudential Financial Inc. Acquires 152,992 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Shares Sold by HighTower Advisors LLC - MarketBeat
Eli Lilly Alzheimer’s Drug Kisunla Fails to Get EU Backing - Mint
European Drug Regulator Gives Thumbs Down To Eli Lilly's Alzheimer's Drug, Analyst Says It Is Incremental Win For Biogen - Benzinga
Lilly hits same Alzheimer’s roadblock in Europe as Eisai, Biogen - BioPharma Dive
Trend Tracker for (BIIB) - Stock Traders Daily
Mizuho Securities USA LLC Raises Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Shares Acquired by Teacher Retirement System of Texas - MarketBeat
Natixis Advisors LLC Reduces Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Hillsdale Investment Management Inc. Buys Shares of 4,610 Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Stock Holdings Trimmed by Northwest & Ethical Investments L.P. - MarketBeat
BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
Biogen: Balancing Risks And Opportunities - Seeking Alpha
Biogen plans new headquarters at Kendall Common - MSN
Beyond GLP-1 Drugs: This Opportunity at Eli Lilly Could Surprise Everyone in 2025 - The Motley Fool
Lilly adds Alzheimer's to online offerings - Marketscreener.com
6,175 Shares in Biogen Inc. (NASDAQ:BIIB) Acquired by Crowley Wealth Management Inc. - MarketBeat
Vanguard Group Inc. Raises Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen to Move Global Headquarters to Kendall Commons in 2028 - Harvard Crimson
1,874 Shares in Biogen Inc. (NASDAQ:BIIB) Purchased by Vinva Investment Management Ltd - MarketBeat
Sector Gamma AS Sells 6,166 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
BIOGEN TO REPORT FIRST QUARTER 2025 FINANCIAL RESULTS MAY 1, 2025 - Biogen | Investor Relations
Roche Voids Biogen's Protein Production Patent At EPO - Law360
Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your RightsBIIB - ACCESS Newswire
Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square - Boston Real Estate Times
Cassava Sciences shuts down Alzheimer's programshares plummet - Marketscreener.com
KLP Kapitalforvaltning AS Acquires Shares of 92,377 Biogen Inc. (NASDAQ:BIIB) - MarketBeat
News | Blackstone’s BioMed adds biotech hub in Boston area with added demand - CoStar Group
7 Stocks Still Trading Below COVID Lows 5 Years Later - MSN
Biogen to Relocate Headquarters to New Development by MIT and BioMed - Connect CRE
Biogen to consolidate operations at new global headquarters in Cambridge - FirstWord Pharma
Biogen plots new global headquarters in Kendall Square - BioPharma Dive
Biogen Relocating to MIT Development in Cambridge - Banker & Tradesman
Biogen Signs Lease for New Global HQ in Cambridge, Massachusetts -March 24, 2025 at 09:37 am EDT - Marketscreener.com
Biogen Plans New Global Headquarters in Cambridge, Massachusetts -March 24, 2025 at 08:18 am EDT - Marketscreener.com
Biogen to establish new HQ in Cambridge by 2028 - Investing.com
Biogen Plans For State-of-the-Art Global Headquarters At Kendall Common, Set To Open In 2028 - Nasdaq
Biogen Announces Plans For New Global Headquarters And Innovation Hub In Kendall Square - Marketscreener.com
Biogen to move HQ to new tower in MIT Kendall development - The Business Journals
Biogen Inc. (NASDAQ:BIIB) Shares Sold by Commonwealth Equity Services LLC - MarketBeat
Biogen to move its Cambridge headquarters in 2028 - The Boston Globe
Harvest Fund Management Co. Ltd Increases Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Generali Investments Management Co LLC Makes New $410,000 Investment in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Intech Investment Management LLC Makes New Investment in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
OVERSEA CHINESE BANKING Corp Ltd Grows Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc Stock (BIIB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):